PANGSON CHEMPHARM BIOTECHNOLOGY INC.
PANGSON CHEMPHARM BIOTECHNOLOGY INC.
New York, United States

COMPANY OVERVIEW

Company Album2

Basic Information
Pangson Chempharm International LLC.( Abbreviate: PCI. Its subsidiary: Pangson Chempharm Biotchnology Inc.) Was established in 2012 with the registrations in New Mexico and New York State. Its predecessor is GenesTch New York Inc. (established in 2000.) As a world-wide leading supplier, Pangson is mainly engaged in pharmaceuticals products, chemicals products, sports nutrients, dietary supplements, vitamins,food additives, amino acid products and plant extraction. Since its establishment,we have been always growing vigorously along with our manufactures and business partners. Currently, the company has built great business relationship with many trading partners worldwide including Germany, Spain, Chile, Portugal,Canada, South Korea, Australia, Mexico, Egypt, Brazil, Turkey, France, Britain,Columbia and Eastern Europe. Pangson has always been serving our customers with a strong sense of responsibility and at the efficient working mentality,providing products with highest-quality and competitive prices to the customers. Pangson has always been following the goal of "Customer is our priority, we should do our best for all our customers." Dear customers, if you give us the opportunity, we will reward you a healthy life! We welcome all inquiries and always get ready for new business relationships and growing opportunities together with Pangson !
  • Transactions
    -
Business type
Manufacturer
Country / Region
New York, United States
Main ProductsTotal employees
5 - 10 People
Total Annual Revenue
Above US$100 Million
Year established
2015
Certifications
-
Product Certifications
-
Patents
-
Trademarks
-
Main Markets

PRODUCT CAPACITY

Factory Information

Factory Size
Above 100,000 square meters
Factory Country/Region
P.O BOX 4005 North Sanjing Road Yangliuqing Xiqing District TIANJIN,China.
No. of Production Lines
Above 10
Contract Manufacturing
Buyer Label Offered
Annual Output Value
Above US$100 Million

R&D CAPACITY

Research & Development

41 - 50 People

TRADE CAPABILITIES

Main Markets & Product(s)

Main markets
Total Revenue(%)
Main Product(s)
Verified
South America
30.00%
North America
20.00%
Domestic Market
10.00%
Southeast Asia
10.00%
Eastern Europe
10.00%
Western Europe
5.00%
Southern Europe
3.00%
Oceania
3.00%
Eastern Asia
3.00%
Africa
3.00%
South Asia
2.00%
Mid East
1.00%
Verified

Trade Ability

Language Spoken
English, Chinese
No. of Employees in Trade Department
11-20 People
Average Lead Time
7
Total Annual Revenue
Above US$100 Million

Business Terms

Accepted Delivery Terms
FOB, CFR, CIF, EXW, Express Delivery
Accepted Payment Currency
USD
Accepted payment methods
T/T, L/C, MoneyGram
Nearest Port
Tianjin China, NEW YORK, LA